Protein kinase antagonists: Interim challenges and issues

Anti-Cancer Drug Design

Volumn 15, Issue 1, 2000, Pages 1-2

  Sausville, Edward A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE INHIBITOR;

PRIORITY JOURNAL; SHORT SURVEY;

ENZYME INHIBITORS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SUBSTRATE SPECIFICITY;

EID: 0034119931     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (6)

1. Akinaga S., Sugiyama K., Akiyama T. (2000) UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: a new generation of anti-cancer agents for the new century? Anti-Cancer Drug Design, 15, 43.
2. Fabbro D., Ruetz S., Bodis S., Pruschy M., Csermak K., Man A., Campochiaro P., Wood J., O'Reilly T., Meyer T. (2000) PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anti-Cancer Drug Design, 15, 17.
3. Fry D.W. (2000) Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anti-Cancer Drug Design, 15, 3.
4. Gussio R., Zaharevitz D.W., McGrath C.F., Pattabiraman N., Kellogg G.E., Schultz C., Link A., Kunick C., Leost M., Meijer L., Sausville E.A. (2000) Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition. Anti-Cancer Drug Design, 15, 53.
5. Hunter, T. (1994) 10001 protein kinases redux: towards 2000. Seminars in Cell Biology, 5, 367.
6. Mendel D.B., Laird A.D., Smolich B., Blake R.A., Liang C., Hannah A.L., Shaheen R.M., Ellis L.M., Weitman S., Shawver L.K., Cherrington J.M. (2000) Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anti-Cancer Drug Design, 15, 29.